$65.00 Original price was: $65.00.$45.00Current price is: $45.00.
25 in stock
CAS Number: 80714-61-0
Molecular Formula: C₄₉H₇₄N₁₄O₁₁
Molar Mass: 1034.2 g/mol
Purity: ≥98% (HPLC)
Form: Sterile nasal spray solution
Concentration: Customizable per research protocol
Semax is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH), extensively studied for its neuroprotective, nootropic, and cognitive-enhancing properties. Delivered as a nasal spray, Semax demonstrates rapid absorption through the nasal mucosa, making it an effective tool for preclinical investigations into neurodegenerative diseases, cognitive function, and neuroplasticity.
CombatResearch.io provides pharmaceutical-grade Semax Nasal Spray tailored for in vivo and in vitro research in neuroscience and pharmacology.
Neuroprotection and neuroplasticity studies
Cognitive enhancement and memory research
Stroke and ischemia models
Nootropic mechanism investigations
Nasal peptide delivery and pharmacokinetics
Store refrigerated at 2–8°C
Protect from light and moisture
Use sterile techniques for all handling and dosing
For Research Use Only. Not for Human or Veterinary Use.
Semax nasal spray is sold exclusively for laboratory research. It is not FDA approved and is not intended for human therapeutic use or consumption. Researchers must comply with all relevant laws and safety protocols.
Only logged in customers who have purchased this product may leave a review.
$106.00 Original price was: $106.00.$88.00Current price is: $88.00.
Please be advised: All compounds and research materials provided by Combat Research are strictly for laboratory and research use only. They are not approved for human consumption by the Food and Drug Administration (FDA). These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
© 2024, All Right Reserved
Reviews
There are no reviews yet.